Table 4.

Hematological adverse events (grade 4)

Variable, n (%), (n = 30)	Initial dose of irinotecan in the first cycle of treatment
	≥ 150 mg/m2	120 mg/m2	90–100 mg/m2	70–80 mg/m2	≤ 60 mg/m2
Neutropenia	4 (67)	1 (25)	3 (27)	1 (20)	0
Thrombocytopenia	0	0	0	0	0